Patents by Inventor Svante Hermodsson

Svante Hermodsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treatment of cancer and infectious disease
    Patent number: 6003516
    Abstract: Method for treatment of cancer and infectious disease comprises administering a first composition containing interferon-.alpha. or analogues thereof, together with a second composition containing at least one substance with H.sub.2, or 5-HT.sub.1A, receptor agonist activity, for example, histamine or serotonin. The first and second compositions are either mixed in a preparation or furnished in separate doses.
    Type: Grant
    Filed: March 2, 1998
    Date of Patent: December 21, 1999
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson
  • Stable circulating histamine levels
    Patent number: 5961969
    Abstract: Methods for obtaining beneficial stable levels of circulating histamine are disclosed for use in methods for enhancing natural killer cell cytotoxicity. In such methods, a beneficial level of circulating histamine is attained and an agent whose ability to enhance natural killer cell cytotoxicity is augmented by histamine is administered. Alternatively, stable beneficial levels of circulating histamine can be attained in subjects receiving chemotherapy or antiviral treatment. The invention may also be employed in treatments combining histamine, agents which enhance natural killer cell cytotoxicity, and chemotherapeutic agents.
    Type: Grant
    Filed: May 14, 1996
    Date of Patent: October 5, 1999
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson
  • Preparation for activation of natural killer cells (NK-cells), said preparation containing interferon-alpha and histamine, serotonin, amines or substances with corresponding receptor activity
    Patent number: 5728378
    Abstract: Pharmaceutical preparation or system for activation of natural killer cells (NK cells), for example in order to treat tumors or virus infections, and which comprises a first composition containing interferon-.alpha. or analogues thereof, together with a second composition containing at least one substance with H.sub.2, or 5-HT.sub.1A, receptor agonist activity, for example, histamine or serotonin. The first and second compositions are either mixed in a preparation or furnished in separate doses.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: March 17, 1998
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson